PMID- 25630605
OWN - NLM
STAT- MEDLINE
DCOM- 20151123
LR  - 20220419
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 14
IP  - 4
DP  - 2015 Apr
TI  - Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
PG  - 505-24
LID - 10.1517/14740338.2015.1006625 [doi]
AB  - INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) occupy a 
      growing place in the armamentarium of drugs used for the management of 
      hyperglycemia in type 2 diabetes, although some safety concerns have been raised 
      in recent years. AREAS COVERED: An updated review providing an analysis of 
      available safety data (meta-analyses, randomized controlled trials, observational 
      cohort and case-control studies and pharmacovigilance reports) with five 
      commercialized DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, 
      alogliptin, linagliptin). A special focus is given to overall safety profile; 
      pancreatic adverse events (AEs) (acute pancreatitis, pancreatic cancer); overall 
      cardiovascular safety (myocardial infarction and stroke); congestive heart 
      failure concern and finally, safety in special populations (elderly, renal 
      impairment). EXPERT OPINION: The good tolerance/safety profile of DPP-4 
      inhibitors has been largely confirmed, including in more fragile populations 
      (elderly, renal impairment) with almost no increased risk of infection or 
      gastrointestinal AEs, no weight gain and a minimal risk of hypoglycemia. Although 
      an increased risk of acute pancreatitis and pancreatic cancer was suspected, the 
      complete set of available data appears reassuring so far. Cardiovascular safety 
      of DPP-4 inhibitors has been proven but an unexpected increased risk of heart 
      failure has been reported which should be confirmed in ongoing trials and better 
      understood. Further postmarketing surveillance is recommended.
FAU - Scheen, Andre J
AU  - Scheen AJ
AD  - University of Liege, CHU Sart Tilman, Division of Diabetes, Nutrition and 
      Metabolic Disorders, Department of Medicine , (B35), B-4000 Liege 1 , Belgium +32 
      4 3667238 ; +32 4 3667068 ; andre.scheen @ chu.ulg.ac.be.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150129
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*adverse effects/therapeutic use
MH  - Humans
MH  - Hyperglycemia/drug therapy/etiology
MH  - Hypoglycemia/chemically induced/epidemiology
MH  - Hypoglycemic Agents/*adverse effects/therapeutic use
OTO - NOTNLM
OT  - cardiovascular outcome
OT  - dipeptidyl peptidase-4 inhibitor
OT  - heart failure
OT  - pancreas
OT  - safety
OT  - special population
OT  - type 2 diabetes mellitus
EDAT- 2015/01/30 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/01/30 06:00
PHST- 2015/01/30 06:00 [entrez]
PHST- 2015/01/30 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1517/14740338.2015.1006625 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2015 Apr;14(4):505-24. doi: 10.1517/14740338.2015.1006625. 
      Epub 2015 Jan 29.